Loading…
SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.
Also known as: AMYLIN PHARMACEUTICALS
Client-Reported Lobbying Expenses
$6.8M
31 filings
Firm Income Reported for This Client
$60K
Not substituted for client expenses
Summary
AMYLIN PHARMACEUTICALS is an organization, based in DC. Its political footprint includes $6.8 million in client-reported lobbying expenses, $60K in lobbying-firm income reported for this client. Lobbying activity focuses on Medicare/Medicaid, Pharmacy, Copyright/Patent/Trademark, Health Issues. Political activity spans from 2006 to 2012.
These are different money flows and are not added together: contributions and lobbying expenses flow out, while contract awards flow to the organization.
Lobbying Spend Trend
↓ 20% YoY
2012: $770K (complete years)
Activity data: Senate LDA